Skip to main content

Bausch Health Companies Inc.

BHC
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0000885590

In the last 90 days, Bausch Health Companies Inc. insiders filed 0 open-market purchases and 1 sale; 219 institutions reported holding it in 13F filings for Q2 2026, worth $1.18B in total; no superinvestor holds it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Bausch Health Companies Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
1 filing
1 insider, $258.9K in total
Insiders trading
1
Net value
−$258.9K
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Bausch Health Companies Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Bausch Health Companies Inc.
NameTitleLast reported holdingLast filingFilings, past year
Lenar Aimee J.President, US Pharma334,853Aug 20, 20264
Lee Steven HyosigSVP, Controller & CAO70,114Jul 15, 20262
Wechsler Amy BDirector314,979Jul 2, 20265
Paulson JohnDirector430,242Jul 2, 20265
Leung SandraDirector97,070Jul 2, 20265
Power Robert NDirector300,594May 26, 20261
Garcia Christian ADirector135,578May 26, 20261
Kavanagh Sarah BDirector282,230May 26, 20261
Roberts EiryDirector45,871May 26, 20261
Goettler MichaelDirector76,020May 26, 20261
Lee Frank D.Director95,210May 26, 20262
Appio ThomasChief Executive Officer2,315,374Mar 3, 20263
Charhon Jean-JacquesEVP, CFO706,478Mar 3, 20262
Carson SeanaEVP, General Counsel616,761Mar 3, 20263
Paulson & Co. Inc.10% Owner73,255,869IndirectNov 28, 20251
Icahn BrettDirector220,280Jul 2, 20250
Mulligan RichardDirector155,616May 20, 20250
Miller Steven DDirector229,224May 20, 20250
Barresi John SSVP, Controller & CAO192,268Mar 3, 20250
Robertson Russel CDirector225,279Apr 1, 20240
Vadaketh Tom GeorgeEVP, Chief Financial Officer564,933Sep 6, 20230
Ross Thomas W. Sr.Director161,516May 19, 20230
De Schutter Richard UDirector373,407Apr 4, 20230
Karabelas Argeris NDirector123,715Jun 28, 20220
Papa Joseph CDirector1,427,568May 12, 20220
Spurr RobertPresident, U.S. Businesses112,741May 12, 20220
Munsch FrederickSVP, Controller and CAO22,435May 5, 20220
Ackermann ChristinaEVP AND GENERAL COUNSEL162,240Mar 11, 20220
Gordon Joseph FPres&Co-Head Bausch&Lomb/Int'l93,139Mar 10, 20220
Eldessouky SamEVP & Chief Financial Officer119,455Mar 7, 20220
Von Eschenbach Andrew C.Director38,647Aug 9, 20210

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Aug 20, 2026 (view filing)4:33 PM ETAug 191 dayLenar Aimee J.President, US PharmaSSaleCommon Shares, No Par Value−36.8K$7.03−$258.9K−9.9%334.9K after10b5-1
May 20, 2026 (view filing)May 191 dayLee Frank D.DirectorSSaleCommon Shares, No Par Value−24.5K$5.43−$132.8K−33.1%49.3K after10b5-1
Mar 3, 2026 (view filing)Mar 2-31 dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−11.3K$5.78−$65.1K−1.8%616.8K after2 lots10b5-1
Feb 27, 2026 (view filing)Feb 27Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−8.39K$5.95−$49.9K−1.0%809.3K after10b5-1
Nov 28, 2025 (view filing)Nov 253 daysPaulson & Co. Inc.10% OwnerPPurchaseCommon Stock, no par value+2.50M$6.25+$15.6M+3.5%73.3M after
Sep 8, 2025 (view filing)Sep 8Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−13.4K$7.31−$97.7K−2.6%499.6K after10b5-1
Aug 22, 2025 (view filing)Aug 211 dayLee Frank D.DirectorSSaleCommon Shares, No Par Value−15.9K$7.66−$121.9K−17.7%73.8K after
Aug 14, 2025 (view filing)Aug 14Same dayPaulson JohnDirectorPPurchaseCommon Stock, no par value+34.7M$9.00+$312.5M+96.4%70.8M after
Aug 13, 2025 (view filing)Aug 11-132 daysPaulson JohnDirectorPPurchaseCommon Stock, no par value+3.24M$6.56+$21.3M+9.9%36.0M after3 lots
Jun 17, 2025 (view filing)Jun 134 daysPaulson JohnDirectorPPurchaseCommon Stock, no par value+3.56M$5.94+$21.2M+12.2%32.8M after
Jun 12, 2025 (view filing)Jun 10-122 daysPaulson JohnDirectorPPurchaseCommon Stock, no par value+2.79M$5.27+$14.7M+10.5%29.2M after3 lots
Dec 3, 2024 (view filing)Dec 21 dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−440$8.35−$3.67K−0.1%433.1K after10b5-1
Sep 9, 2024 (view filing)Sep 63 daysCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−13.4K$6.21−$83.0K−3.0%435.2K after10b5-1
Mar 4, 2024 (view filing)Mar 4Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−6.31K$9.80−$61.9K−1.2%499.9K after4 lots10b5-1
Dec 5, 2023 (view filing)Dec 5Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−220$7.38−$1.62K−0.1%382.9K after10b5-1
Nov 6, 2023 (view filing)Nov 6Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−43$7.61−$327.230.0%384.8K after10b5-1
Sep 6, 2023 (view filing)Sep 6Same dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−6.68K$8.28−$55.4K−1.7%385.2K after10b5-1
Mar 7, 2023 (view filing)Mar 3-64 daysCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−1.27K$9.27−$11.8K−0.3%443.2K afterAmended2 lots
Mar 1, 2023 (view filing)Feb 281 dayCarson SeanaEVP, General CounselSSaleCommon Shares, No Par Value−292$9.32−$2.72K−0.1%359.2K after
Apr 15, 2022 (view filing)Apr 141 daySpurr RobertU.S. President-Pharma BusinessSSaleCommon Shares, No Par Value−1.59K$22.19−$35.4K−1.7%90.5K after
Mar 16, 2022 (view filing)Mar 151 daySpurr RobertU.S. President-Pharma BusinessSSaleCommon Shares, No Par Value−4.85K$22.20−$107.6K−5.0%92.1K after
Mar 10, 2022 (view filing)Mar 82 daysGordon Joseph FPres&Co-Head Bausch&Lomb/Int'lSSaleCommon Shares, No Par Value−3.89K$21.76−$84.6K−4.0%93.1K after
Mar 4, 2022 (view filing)Mar 22 daysGordon Joseph FPres&Co-Head Bausch&Lomb/Int'lSSaleCommon Shares, No Par Value−11.1K$23.37−$258.9K−9.9%101.1K after
Mar 4, 2022 (view filing)Mar 22 daysSpurr RobertU.S. President-Pharma BusinessSSaleCommon Shares, No Par Value−1.59K$23.37−$37.3K−2.4%65.4K after
Mar 2, 2022 (view filing)Mar 11 dayGordon Joseph FPres&Co-Head Bausch&Lomb/Int'lSSaleCommon Shares, No Par Value−6.34K$23.82−$151.0K−5.3%112.2K after
Feb 17, 2022 (view filing)Feb 152 daysSpurr RobertU.S. President-Pharma BusinessSSaleCommon Shares, No Par Value−3.25K$25.02−$81.3K−5.1%60.3K after
Jan 20, 2022 (view filing)Jan 182 daysSpurr RobertU.S. President-Pharma BusinessSSaleCommon Shares, No Par Value−3.25K$26.63−$86.6K−4.9%63.5K after
Dec 2, 2021 (view filing)Nov 302 daysMiller Steven DDirectorPPurchaseCommon Shares, No Par Value+50.0K$24.24+$1.21M+463.8%60.8K after
Dec 2, 2021 (view filing)Nov 302 daysMiller Steven DDirectorPPurchaseCommon Shares, No Par Value+10.0K$24.17+$241.7KNew position10.0K after
Aug 9, 2021 (view filing)Aug 54 daysVon Eschenbach Andrew C.DirectorPPurchaseCommon Shares, No Par Value+1.40K$25.94+$36.3K+3.8%38.6K after
Aug 6, 2021 (view filing)Aug 42 daysDe Schutter Richard UDirectorPPurchaseCommon Shares, No Par Value+10.0K$25.01+$250.1K+3.3%317.1K after